Akebia Therapeutics, Inc.

Akebia Therapeutics reported a net loss of $(8.9) million for the second quarter of 2026, a significant decline from a net income of $0.2 million in the same period last year. Total revenues also decreased to $49.1 million from $62.5 million year-over-year. The company continues to incur losses and anticipates needing additional financing, citing the impact of generic competition for Auryxia and potential challenges with Vafseo revenue projections.

Akebia Therapeutics reported Q2 2026 financial results, with Vafseo net product revenues growing 34% sequentially to $21.3 million. However, total revenues decreased to $49.1 million, primarily due to lower Auryxia sales, resulting in a net loss of $8.9 million. The company also announced positive interim results from the VOICE trial for Vafseo, the initiation of a Phase 2 trial for ebribafusp, and strengthened its Vafseo intellectual property portfolio.

Akebia Therapeutics announced the initiation of a Phase 2 basket trial for ebribafusp, an anti-C3d factor H fusion protein, to evaluate its safety, efficacy, and pharmacokinetics in rare complement-mediated kidney diseases. The trial will target IgA nephropathy, lupus nephritis, and C3 glomerulopathy, enrolling up to 30 patients. Ebribafusp is designed to inhibit complement activation in tissues without affecting the complement system in the blood, potentially offering a safer treatment option. Initial data from the trial is anticipated in 2027.

Akebia Therapeutics, Inc. announced its plan to release financial results for the second quarter ended June 30, 2026, on Wednesday, August 5, 2026, after market close. The company will host a conference call on the same day at 4:30 p.m. EDT to discuss the results and recent business highlights. Details for accessing the call via phone or webcast were provided.

Akebia Therapeutics, Inc. announced it granted stock options to three newly-hired employees on June 30, 2026. These options allow the purchase of an aggregate of 125,600 shares of Akebia's common stock at an exercise price of $1.14 per share. The options vest over four years, with 25% vesting on the first anniversary and the remainder quarterly thereafter, contingent on continued employment.

Akebia Therapeutics and U.S. Renal Care announced that the Vafseo Outcomes In Center Experience (VOICE) trial met its predefined stopping criteria during a planned interim analysis. The trial demonstrated non-inferiority and superiority of Vafseo for the primary composite endpoint of all-cause mortality and hospitalization, leading to the decision to stop the trial early. Results showed a statistically significant reduction in hospitalizations with Vafseo compared to standard-of-care erythropoiesis stimulating agents (ESA).

Akebia Therapeutics granted stock options for 8,400 shares of its common stock to a newly-hired employee on May 29, 2026. The options, with an exercise price of $1.02 per share, were an inducement for employment and will vest over four years, subject to continued service. This grant was made in accordance with Nasdaq Listing Rule 5635(c)(4) and has a 10-year term.

Akebia Therapeutics announced that its Chief Financial and Business Officer, Erik Ostrowski, and Chief Commercial Officer, Nicholas Grund, will present at the 2026 Jefferies Global Healthcare Conference. The presentation is scheduled for Thursday, June 4, 2026, at 7:35 AM ET in New York, NY. A live webcast and a 90-day replay will be accessible through the company's investor relations website.

Akebia Therapeutics reported a net loss of $9.05 million for the first quarter of 2026, a significant decline from a net income of $6.11 million in the prior year. Total revenues decreased by 6.6% to $53.54 million, primarily due to a drop in product revenue. The company also noted the entry of a generic version of its Auryxia product into the market in March 2026, following its loss of exclusivity in March 2025, which is expected to impact future revenue. Akebia anticipates continued losses and may require additional financing.

Akebia Therapeutics reported a net loss of $9.1 million for the first quarter of 2026, a significant shift from a net income of $6.1 million in Q1 2025. Total revenues decreased to $53.5 million, primarily due to lower Auryxia sales, despite Vafseo net product revenues growing to $15.8 million. The company also highlighted commercial growth for Vafseo, with a 60% increase in patients, and progress in its kidney disease pipeline, including ongoing Phase 2 trials for praliciguat and plans for new studies for AKB-097 and AKB-9090.